Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States
Among United States Medicare Optum CDM enrolees with T2D and ASCVD, semaglutide was associated with reduced risks of CV outcomes compared with dulaglutide. These results help to address an important evidence gap in selecting glucagon-like peptide-1 receptor agonists for this high-risk population.
Authors
- CAROLINE SWIFT (ORCID: https://orcid.org/0000-0003-3192-1200)
- Chalak Muhammad
- Lin Xie (ORCID: https://orcid.org/0000-0002-7058-0851)
- XI TAN
- Yuanjie Liang (ORCID: https://orcid.org/0000-0003-4566-0865)
- Adam de Havenon
- Cynthia Gutierrez
- Joanna Harton
Institutions
- Yale University (US)
- Novo Nordisk (United States) (US)
- Yale New Haven Health System (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1111/dom.70440
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk